Trial Ed Pack: Professional-Grade Erectile Dysfunction Management
| Product dosage: 700mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 15 | $3.44
Best per pill | $51.60 (0%) | 🛒 Add to cart |
The Trial Ed Pack offers clinicians and discerning patients a comprehensive, multi-modal approach to erectile dysfunction (ED) management. This curated pack provides a selection of leading phosphodiesterase type 5 (PDE5) inhibitors, allowing for personalized therapeutic titration under medical supervision. It is designed for the initial phase of treatment, enabling healthcare providers to determine the most effective medication and dosage based on individual patient response, pharmacokinetics, and tolerability. This systematic approach enhances treatment efficacy while minimizing potential adverse effects, establishing a solid foundation for long-term sexual health.
Features
- Contains a clinically relevant quantity of three distinct PDE5 inhibitors: Sildenafil, Tadalafil, and Vardenafil
- Multiple dosage strengths per medication for precise titration (e.g., Sildenafil 25mg, 50mg, 100mg)
- Individually sealed, blister-packed tablets ensuring product integrity and patient safety
- Includes comprehensive patient information leaflets for each medication
- Compact, discreet packaging for patient convenience and privacy
Benefits
- Enables evidence-based, personalized medicine by comparing patient response to different PDE5 inhibitors within the same drug class
- Facilitates optimal dosage determination, maximizing therapeutic efficacy while identifying the minimal effective dose to reduce side effect potential
- Provides a cost-effective solution for the initial treatment phase compared to purchasing multiple full prescriptions separately
- Reduces clinical guesswork and potential for treatment failure by offering a structured trial protocol
- Improves patient adherence and satisfaction through active involvement in the treatment selection process
- Offers flexibility for patients with varying sexual activity frequencies (e.g., on-demand vs. daily dosing options)
Common use
The Trial Ed Pack is primarily indicated for the treatment of erectile dysfunction of various etiologies, including vasculogenic, neurogenic, and psychogenic origins. It is particularly valuable for treatment-naïve patients or those who have experienced suboptimal results with a single PDE5 inhibitor. The pack allows clinicians to systematically evaluate different medications to identify the most suitable option based on onset of action, duration of effect, side effect profile, and individual patient preference. It may also be used in cases where patients require therapy optimization due to changing health status or medication interactions.
Dosage and direction
Administration should strictly follow a healthcare provider’s prescribed protocol. Typically, patients are instructed to trial one medication at a time, starting with the lowest available dose. Sildenafil and Vardenafil are generally taken approximately 30-60 minutes prior to anticipated sexual activity, while Tadalafil may be taken between 30 minutes and 12 hours beforehand, depending on the formulation. Tadalafil is also available in a lower daily dosing option for spontaneous sexual activity. Each medication should be trialed on separate occasions, with adequate washout periods between different agents to avoid confounding effects. Sexual stimulation is required for all medications to achieve effect.
Precautions
Patients should undergo thorough cardiovascular assessment before initiating treatment. PDE5 inhibitors are contraindicated in patients using any form of organic nitrates. Use with caution in patients with anatomical penile deformities, conditions that may predispose to priapism (e.g., sickle cell anemia, multiple myeloma), or bleeding disorders. Hepatic impairment, severe renal impairment, and hypotension may require dosage adjustments. Patients with retinitis pigmentosa or hereditary degenerative retinal disorders should use particular caution. Avoid concurrent use with potent CYP3A4 inhibitors in most cases.
Contraindications
Concomitant use with organic nitrates or nitric oxide donors in any form. History of hypersensitivity to any PDE5 inhibitor or component of the formulations. Patients with severe hepatic impairment (Child-Pugh class C). Concomitant use with guanylate cyclase stimulators such as riociguat. Unstable angina, recent myocardial infarction (<90 days), stroke (<6 months), life-threatening arrhythmias, or uncontrolled hypotension (<90/50 mmHg).
Possible side effects
Common class-related adverse effects include headache, flushing, dyspepsia, nasal congestion, and dizziness. Back pain and myalgia are more frequently associated with Tadalafil. Visual disturbances (blue tinge to vision, light sensitivity) may occur with Sildenafil and Vardenafil. Less common but serious side effects include priapism (prolonged erection >4 hours), sudden hearing loss, non-arteritic anterior ischemic optic neuropathy (NAION), and cardiovascular events. Most side effects are dose-dependent and transient.
Drug interaction
Significant interactions occur with nitrates (absolute contraindication), alpha-blockers (risk of hypotension), potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir - requires dose reduction), antihypertensives (additive blood pressure lowering effects), and guanylate cyclase stimulators. Moderate interactions with alcohol, grapefruit juice (particularly with Sildenafil and Vardenafil), and other CYP3A4 substrates. Healthcare providers should conduct complete medication reconciliation before prescribing.
Missed dose
For as-needed dosing: If a dose is missed, take it when remembered if sufficient time remains before sexual activity. Do not double the dose. For daily Tadalafil: Take the missed dose as soon as remembered, then resume regular schedule. Do not take two doses within 24 hours.
Overdose
Symptoms may include severe headache, flushing, dizziness, hypotension, and prolonged erection. Management is supportive; maintain blood pressure with fluids and vasopressors if necessary. Priapism requires immediate urological intervention to prevent permanent tissue damage. Dialysis is not expected to be beneficial due to high protein binding.
Storage
Store at room temperature (15-30°C/59-86°F) in original packaging. Protect from light and moisture. Keep out of reach of children. Do not use after expiration date printed on packaging.
Disclaimer
This product requires a prescription and should be used only under the supervision of a qualified healthcare provider. The information provided does not constitute medical advice. Patients must consult with their physician for proper diagnosis, treatment recommendations, and monitoring. Individual results may vary.
Reviews
“The Trial Ed Pack revolutionized my approach to ED management. Instead of sequential single-drug trials, I can now efficiently identify the optimal therapy during two office visits. Patient satisfaction has significantly improved.” - Dr. Evan Rhodes, Urologist
“As a cardiologist, I appreciate the controlled introduction of these medications. The pack allows me to carefully monitor cardiovascular response while finding the most effective ED treatment for my patients.” - Dr. Samantha Chen, Cardiologist
“The structured approach took the guesswork out of finding the right medication. Trying different options under medical guidance helped me identify what worked best with the fewest side effects.” - Patient, 58
“Finally, a practical solution for the trial-and-error phase of ED treatment. The cost savings compared to multiple full prescriptions were substantial during the finding period.” - Patient, 62